MGFA Study Web Content:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

**Study Purpose:** The primary objective of the study is to assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) profile.

**Recruitment Information:**

**Study Type:** This interventional study is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the safety and efficacy of Ravulizumab in complement-inhibitor-naïve adult patients with generalized Myasthenia Gravis

**Status:** Recruiting

**Target Patient:** A male or female (aged 18 years or older) with a diagnosis of generalized Myasthenia Gravis (MG) meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) Class II to IV.

**Eligible Ages:** ≥ 18 years

*Link to appropriate websites*


**Inclusion and Exclusion Criteria:**

**Inclusion Criteria:** Patients diagnosed with Myasthenia Gravis at least 6 months prior to the date of the Screening Visit as confirmed by specific criteria. Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening. Patients must be vaccinated against meningococcal infections within 3 years prior to, or at the time of, initiating study drug to reduce the risk of meningococcal infection (N meningitidis). Other, more specific inclusion criteria are further defined in the protocol.
Exclusion Criteria: Any active or untreated thymoma. History of thymic carcinoma or thymic malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening. History of thymectomy within the 12 months prior to screening. History of N meningitidis infection. Participants who have received previous treatment with complement inhibitors (for example, eculizumab). Other, more specific exclusion criteria are further defined in the protocol.

Study Information:

Sponsor: Alexion Pharmaceuticals, Inc.

Principal Investigator: Click here to enter text.

Study Coordinator: Click here to enter text.

Type of Study: Interventional

Study Duration: 132 weeks

Single Center/Multi-center: Multi-center

Travel Funds Available: ☒ Y ☐ N

For more information, contact: clinicaltrials@alexion.com

Find A Center Near You:

List Sites Here

Site: Click here to enter text.

PI: Click here to enter text.

Coordinator: Click here to enter text.